References
- 1. Ma Q, Lu AY. Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev. 2011; 63(2): 437-459.
- 2. Foster MW, Sharp RR. Race, ethnicity, and genomics: Social classifications as proxies of biological heterogeneity. Genome Res. 2002; 12(6): 844-850.
- 3. Stranger BE, Stahl EA, Raj T. Progress and promise of genome-wide association studies for human complex trait genetics. Genetics. 2011; 187(2): 367-383.
- 4. Li J, Zhang L, Zhou H, Stoneking M, Tang K. Global patterns of genetic diversity and signals of natural selection for human ADME genes. Hum Mol Genet. 2011; 20(3): 528-540.
- 5. Sistonen J, Fuselli S, Palo JU, Chauhan N, Padh H, Sajantila A. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scale. Pharmacogenet Genomics. 2009; 19(2): 170-179.
- 6. Yang X, Zhang B, Molony C, Chudin E, Hao K, Zhu J, et al. Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. Genome Res. 2010; 20(8): 1020-1036.
- 7. McGraw J, Waller D. Cytochrome P450 variations in different ethnic populations. Expert Opin Drug Metab Toxicol. 2012; 8(3): 371-382.
- 8. Sim SC, Kacevska M, Ingelman-Sundberg M. Pharmacogenomics of drug-metabolizing enzymes: A recent update on clinical implications and endogenous effects. Pharmacogenomics J. 2013; 13(1): 1-11.
- 9. Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 2009; 41(2): 89-295.
- 10. Rebsamen MC, Desmeules J, Daali Y, Chiappe A, Diemand A, Rey C, et al. The AmpliChip CYP450 test: Cytochrome P450 2D6 genotype assessment and phenotype prediction. Pharmacogenomics J. 2009; 9(1): 34-41.
- 11. Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics. 2007; 17(2): 93-101.
- 12. Kalow W. Pharmacogenetics: A historical perspective. In: McLeod HL, DeVane CL, Haga SB, Johnson JA, Knoel DL, Kolesar JM, et al., Eds. Pharmacogenomics: Application to Patient Care, 2nd ed. Lenexa, KS: American College of Clinical Pharmacy. 2009: 22-31.
- 13. van Schaik RH, van der Heiden IP, van den Anker JN, Lindemans J. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem. 2002; 48(10): 1668-1671.
- 14. Aynacioglu AS, Sachse C, Bozkurt A, Kortunay S, Nacak M, Schröder T, et al. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin Pharmacol Ther. 1999; 66(2): 185-192.
- 15. Buzková H, Pechandová K, Slanar O, Perlik F. Frequency of single nucleotide polymorphisms of CYP-2D6 in the Czech population. Cell Biochem Funct. 2008; 26(1): 76-81.
- 16. Qumsieh RY, Ali BR, Abdulrazzaq YM, Osman O, Akawi NA, Bastaki SM. Identification of new alleles and the determination of alleles and genotypes frequencies at the CYP2D6 gene in Emiratis. PLoS One. 2011; 6(12): e28943. doi: 10.1371/journal.pone.0028943.
- 17. Scordo MG, Caputi AP, D’Arrigo C, Fava G, Spina E. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res. 2004; 50(2): 195-200.
- 18. Bozina N, Granić P, Lalić Z, Tramisak I, Lovrić M, Stavljenić-Rukavina A. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population. Croat Med J. 2003; 44(4): 425-428.
- 19. Arvanitidis K, Ragia G, Iordanidou M, Kyriaki S, Xanthi A, Tavridou A, et al. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. Fundam Clin Pharmacol. 2007; 21(4): 419-426.
- 20. Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, Brockmöller J, Frötschl R, et al. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of Pglycoprotein in a Russian population. Eur J Clin Pharmacol. 2003; 59(4): 303-312.
- 21. Yamada H, Dahl ML, Lannfelt L, Viitanen M, Winblad B, Sjoqvist F. CYP2D6 and CYP2C19 genotypes in an elderly Swedish population. Eur J Clin Pharmacol. 1998; 54(6): 479-481.
- 22. Falzoi M, Pira L, Lazzari P, Pani L. Analysis of CYP2D6 allele frequencies and identification of novel SNPs and sequence variations in Sardinians. ISRN Genet. 2013; 2013. Article ID 204560; http://dx.doi.org/10.5402/ 2013/204560.
- 23. Jakovski K, Kapedanovska Nestorovska A, Labacevski N, Dimovski AJ. Characterization of the most common CYP2C9 and CYP2C19 allelic variants in the population of R. Macedonia. Pharmazie. 2013; 68(11): 893-898.
- 24. Kapedanovska Nestorovska A, Cvetkovska Dimitrovska A, Suturkova Lj. Genetic profile of CYP2C19 polymorphisms in population from Republic of Macedonia. Macedonian Pharmaceutic Bull. 2011; 57(Suppl): 346-348.
- 25. Jakovski K, Kapedanovska Netorovska A, Labacevski N, Dimovski AJ. Frequency of most common CYP3A5 polymorphisms in the healthy population of the Republic of Macedonia. Macedonian Pharmaceutic Bull. 2012; 58(1-2): 25-31.
- 26. Hildebrandt MA, Carrington DP, Thomae BA, Eckloff BW, Schaid DJ, Yee VC, et al. Genetic diversity and function in the human cytosolic sulfotransferases. Pharmacogenomics J. 2007; 7(2): 133-143.
- 27. Horsfall LJ, Zeitlyn D, Tarekegn A, Bekele E, Thomas MG, Bradman N, et al. Prevalence of clinically relevant UGT1A alleles and haplotypes in African populations. Ann Hum Genet. 2011; 75(2): 236-246.
- 28. Polimanti R, Carboni C, Baesso I, Piacentini S, Iorio A, De Stefano GF, et al. Genetic variability of glutathione S-transferase enzymes in human populations: Functional inter-ethnic differences in detoxification systems. Gene. 2013; 512(1): 102-107.
- 29. Sterjev Z, Josifovski T, Panovski M, Sututkova L, Dimovski AJ. The SULT1A1 allele with low potential for estrogen inactivation is associated with reduced colorectal cancer risk in postmenopausal women. Balkan J Med Genet. 2005; 8(3-4): 43-48.
- 30. Bajro MH, Josifovski T, Panovski M, Jankulovski N, Nestorovska AK, Matevska N, et al. Promoter length polymorphism in UGT1A1 and the risk of sporadic colorectal cancer. Cancer Genet. 2012; 205(4): 163-167.
- 31. Sharma R, Hoskins JM, Rivory LP, Zucknick M, London R, Liddle C, et al. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients. Clin Cancer Res. 2008; 14(3): 817-825.
- 32. Wang H, Wang J, Zhao L, Liu X, Mi W. Methylenetetrahydrofolate reductase polymorphisms and risk of acute lymphoblastic leukemia-evidence from an updated meta-analysis including 35 studies. BMC Med Genet. 2012; 4: 13-77.
- 33. Acuña M, Eaton L, Cifuentes L, Massardo D. Genetic variants in the enhancer region of the thymidylate synthase gene in the Chilean population. Br J Clin Pharmacol. 2006; 61(6): 778-782.
- 34. Alzahrani AM, Ragia G, Hanieh H, Manolopoulos VG. Genotyping of CYP2C9 and VKORC1 in the Arabic Population of Al-Ahsa, Saudi Arabia. Biomed Res Int. 2013; 2013: 315980. doi: 10.1155/2013/3159980.
- 35. Matevska N, Josifovski T, Kapedanovska A, Sterjev Z, Serafimoska Z, Panovski M, et al. Methylenetetrahydrofolate reductase C677T polymorphism and risk of colorectal cancer in the Macedonian population. Balkan J Med Genet. 2008; 11(2):17-24.
- 36. Kapedanovska Nestorovska A, Sterjev Z, Serafimoska Z, Josifovski T, Petrusevska N, Suturkova L, et al. Thymidylate synthase enhancer region (TSER) 2R/3R polymorphisms as an independent risk factor for colorectal cancer in Macedonian population. Macedonian Pharmaceutic Bull. 2011; 57(Suppl): 348-349.